Hannu Ryöppönen

• Healthcare Professionals
•  
• Patients
•  
• Investors
•  
• Media
•  
• R&D
•  
• Jobs
•  
• Sustainability
•  
• About us
•  

• Novo Nordisk in brief
• Novo Nordisk way of management
• Management
  • Board of Directors
  • Executive Management
• Corporate governance
• Global offices
• Changing diabetes®
• Changing Possibilities in Haemophilia®
• Download centre
• Contact us

• 
• Print

Board of Directors

Hannu Ryöppönen, Member of the board

Mr Ryöppönen was, until 2009, CFO and deputy CEO in Stora Enso Oyj, FI. Before that he was CFO and executive in Royal Ahold, NL from 2003 to 2005 and served on the Board of Directors of the ICA Group, SE, including the chairmanship of the Audit Committee.

From 1999 to 2003, Mr Ryöppönen was Finance Director of Industri Kapital Group, UK. Mr Ryöppönen served as CFO of the IKEA Group, Denmark, from 1985 to 1998, including a position as deputy CEO of IKANO Asset Management from 1998 to 1999. From 1977 to 1985, Mr Ryöppönen held various management positions at Chemical Bank in the US and the UK, as well as for Alfa Laval in the US and Sweden.

Mr Ryöppönen is the chairman of the Board of Directors of Tiimari Oyj, a member of the Board of Directors of Neste Oil Oyj, Amer Sports Oyj and Rautaruukki Oyj, all in Finland. Mr Ryöppönen is also the Chairman of the Audit Committees of Amer Sports Oyj and Rautaruukki Oyj, and a member of the Audit Committee of Neste Oil Oyj. Finally, Mr Ryöppönen is chairman of the Board of Directors of private equity funds, Altor 2003 GP Limited, Altor Fund II GP Limited and Altor III GP Limited, Jersey, Channel Islands and a member of the Board of Directors of the private equity fund Value Creation Investments Limited, Jersey, Channel Islands.

Mr Ryöppönen has a BA in Business Administration (1976) from Hanken School of Economics, Helsinki.

Mr Ryöppönen was elected to the Board of Directors of Novo Nordisk A/S at the Annual General Meeting in March 2009 for the first time. His term as a board member expires in March 2010.

In March 2009, the Board of Directors of Novo Nordisk A/S elected Mr Ryöppönen as member of the Audit Committee and designated him as financial expert under both Danish and US law.

In February 2010, the Board of Directors of Novo Nordisk A/S assessed that Mr Ryöppönen is regarded as an independent Audit Committee member as defined by the US SEC and an independent board member as defined in Section V.4 of Recommendations for corporate governance designated by the NASDAQ OMX Copenhagen (2008). At the same time, the Board of Directors also assessed that the special competences possessed by Mr Ryöppönen that are important for the performance of his duties are his international executive background and thorough understanding of managing finance operations in global organisations, in particular in relation to accounting, financial and capital markets issues, but also his experience within private equity and Mergers & Acquisitions (M&A).

Mr Ryöppönen is a male Finnish national, born on 25 March 1952.

Back to top